SynthesisCritical care (London, England)2012
Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy.
Synthesis in Critical care (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02759770 (Risk Factors and Prediction Score of ARDS After Cardiac Surgery), which is not on this map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk Factors and Prediction Score of ARDS After Cardiac Surgery
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 178 citations in OpenAlex.
- Probiotic Supplementation Prevents the Development of Ventilator-Associated Pneumonia for Mechanically Ventilated ICU Patients: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.Frontiers in nutrition · 2022Pooled it
- Lung ventilation strategies for acute respiratory distress syndrome: a systematic review and network meta-analysis.Scientific reports · 2016Pooled it
- Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis.Critical care (London, England) · 2015Pooled it
- Ventilator-associated pneumonia in ARDS patients: the impact of prone positioning. A secondary analysis of the PROSEVA trial.Intensive care medicine · 2016Trial
- Acute Respiratory Distress Syndrome in Hospital-Acquired/Ventilator-Associated Pneumonia.Medical sciences (Basel, Switzerland) · 2026Review
- Early versus late 2 mg/kg methylprednisolone therapy in ARDS.Scientific reports · 2025Observational
- 2024 Year in Review: Ventilator-Associated Pneumonia.Respiratory care · 2025Review
- Graphene nanomaterials: A new frontier in preventing respiratory fungal infections.Current medical mycology · 2025Review
- Ultrasound-Mediated Antibiotic Delivery to In Vivo Biofilm Infections: A Review.Chembiochem : a European journal of chemical biology · 2024Review
- Therapeutic characteristics of alveolar-like macrophages in mouse models of hyperoxia and LPS-induced lung inflammation.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Prevalence, predictors, and outcomes of acute respiratory distress syndrome in severe stroke.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Efficacy of compliance with ventilator-associated pneumonia care bundle: A 24-month longitudinal study at Bach Mai Hospital, Vietnam.SAGE open medicine · 2024Article
- Prevention of ventilator-associated pneumonia with inhaled antibiotics.World journal of emergency medicine · 2024Article
- Effect and mechanical mechanism of spontaneous breathing on oxygenation and lung injury in mild or moderate animal ARDS.BMC pulmonary medicine · 2023Article
- Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (VAP) in critically ill patients with COVID-19 or influenza.Annals of intensive care · 2023Article
- Ventilator-associated events: From surveillance to optimizing management.Journal of intensive medicine · 2023Review
- Causative bacteria of ventilator-associated pneumonia in intensive care unit in Bahrain: Prevalence and antibiotics susceptibility pattern.World journal of critical care medicine · 2023Article
- Increased Alveolar Epithelial Damage Markers and Inflammasome-Regulated Cytokines Are Associated with Pulmonary Superinfection in ARDS.Journal of clinical medicine · 2023Article
- Multiple-site decontamination to prevent acquired infection in patients with veno-venous ECMO support.Annals of intensive care · 2023Article
- Ventilator-Associated Pneumonia in COVID-19 Patients Admitted in Intensive Care Units: Relapse, Therapeutic Failure and Attributable Mortality-A Multicentric Observational Study from the OutcomeRea Network.Journal of clinical medicine · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVentilator-associated pneumonia (VAP) may contribute to the mortality associated with acute respiratory distress syndrome (ARDS). We aimed to determine the incidence, outcome, and risk factors of bacterial VAP complicating severe ARDS in patients ventilated by using a strictly standardized lung-protective strategy.
methodsThis prospective epidemiologic study was done in all the 339 patients with severe ARDS included in a multicenter randomized, placebo-controlled double-blind trial of cisatracurium besylate in severe ARDS patients. Patients with suspected VAP underwent bronchoalveolar lavage to confirm the diagnosis.
resultsNinety-eight (28.9%) patients had at least one episode of microbiologically documented bacterial VAP, including 41 (41.8%) who died in the ICU, compared with 74 (30.7%) of the 241 patients without VAP (P = 0.05). After adjustment, age and severity at baseline, but not VAP, were associated with ICU death. Cisatracurium besylate therapy within 2 days of ARDS onset decreased the risk of ICU death. Factors independently associated with an increased risk to develop a VAP were male sex and worse admission Glasgow Coma Scale score. Tracheostomy, enteral nutrition, and the use of a subglottic secretion-drainage device were protective.
conclusionsIn patients with severe ARDS receiving lung-protective ventilation, VAP was associated with an increased crude ICU mortality which did not remain significant after adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.